Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC

NCT01577654 is registered in ClinicalTrials.gov with Endocyte as lead sponsor.

NCT NCT01577654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01577654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Phase 2 Study of EC145 Single-agent and the Combination of EC145 Plus Docetaxel Versus Docetaxel Alone in Participants With Folate-receptor Positive [FR(++)] Second Line NSCLC
Lead sponsor
Endocyte
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
August 31, 2015
Enrollment
203 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer